BF Biosciences Limited (PSX:BFBIO)
Pakistan · Delayed Price · Currency is PKR 126.07
-2.58 (-2.01%)
At close: Oct 19, 2026
BF Biosciences Income Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 9,461 | 5,837 | 3,659 | 1,810 | 1,521 | |
Revenue Growth | 62.08% | 59.55% | 102.19% | 18.99% | -13.34% |
Cost of Revenue | 5,385 | 3,553 | 2,128 | 1,362 | 1,063 |
Gross Profit | 4,076 | 2,285 | 1,531 | 447.24 | 457.77 |
Selling, General & Admin | 2,895 | 1,506 | 757.12 | 158.5 | 187.12 |
Other Operating Expenses | 89.34 | 60.67 | 64.01 | 19.46 | 28.42 |
Operating Expenses | 2,989 | 1,553 | 821.13 | 177.96 | 215.54 |
Operating Income | 1,087 | 731.69 | 709.65 | 269.29 | 242.23 |
Interest Expense | -86.8 | -111.69 | -139.73 | -1.22 | -65.62 |
Interest & Investment Income | 8.19 | 95.02 | 19.34 | 83.4 | 141 |
Currency Exchange Gain (Loss) | -21.56 | -9.08 | -0.11 | -8.18 | 28.15 |
Other Non Operating Income (Expenses) | -16.15 | -12.3 | -9.6 | -151.08 | - |
EBT Excluding Unusual Items | 970.53 | 693.64 | 579.54 | 192.21 | 345.76 |
Gain (Loss) on Sale of Investments | 93.89 | 27.3 | 0.21 | 8.93 | - |
Gain (Loss) on Sale of Assets | 2.99 | 2.79 | 2.13 | 1.06 | 3 |
Pretax Income | 1,067 | 723.74 | 581.88 | 202.2 | 348.76 |
Income Tax Expense | 435.28 | 276.59 | 196.47 | 53.14 | 41.78 |
Net Income | 632.13 | 447.15 | 385.41 | 149.05 | 306.98 |
Net Income to Common | 632.13 | 447.15 | 385.41 | 149.05 | 306.98 |
Net Income Growth | 41.37% | 16.02% | 158.57% | -51.44% | -49.51% |
Shares Outstanding (Basic) | 88 | 81 | 63 | 63 | 63 |
Shares Outstanding (Diluted) | 88 | 81 | 63 | 63 | 63 |
Shares Change | 9.14% | 27.79% | - | 0.01% | - |
EPS (Basic) | 7.16 | 5.52 | 6.09 | 2.35 | 4.85 |
EPS (Diluted) | 7.16 | 5.52 | 6.09 | 2.35 | 4.85 |
EPS Growth | 29.53% | -9.21% | 158.57% | -51.45% | -49.51% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -629.57 | -24.59 | 521.57 | -2,164 | -952 |
Free Cash Flow Per Share | -7.13 | -0.30 | 8.23 | -34.17 | -15.03 |
Gross Margin | 43.08% | 39.13% | 41.84% | 24.72% | 30.10% |
Operating Margin | 11.49% | 12.53% | 19.40% | 14.88% | 15.93% |
Profit Margin | 6.68% | 7.66% | 10.53% | 8.24% | 20.19% |
Free Cash Flow Margin | -6.65% | -0.42% | 14.26% | -119.61% | -62.60% |
EBITDA | 1,360 | 923.61 | 745.21 | 303.06 | 270.23 |
EBITDA Margin | 14.38% | 15.82% | 20.37% | 16.75% | 17.77% |
D&A For EBITDA | 273.58 | 191.92 | 35.57 | 33.78 | 28 |
EBIT | 1,087 | 731.69 | 709.65 | 269.29 | 242.23 |
EBIT Margin | 11.49% | 12.53% | 19.40% | 14.88% | 15.93% |
Effective Tax Rate | 40.78% | 38.22% | 33.76% | 26.28% | 11.98% |
Advertising Expenses | 364.63 | 239.6 | 149.49 | 32.03 | 17 |